Fortrea Expands Early-Phase Capacity with $45 Million Acquisition
Fortrea will buy Worldwide Clinical Trials' Early Phase Services for roughly $45 million in cash, expanding its front-end development across Phases I–IV and adding key Texas facilities. The integration strengthens Fortrea's North American footprint and should streamline operations from first-in-human to proof-of-concept, potentially boosting demand and revenue as the CRO market recovers.
View signal analysis